Inhalation therapy stands as a cornerstone in the effective treatment of chronic respiratory diseases, with current guidelines endorsing it as the preferred route for conditions like asthma and chronic obstructive pulmonary disease (COPD)[1]. At AeproMED, we understand the critical role inhalation therapy plays in improving health outcomes, and we’re dedicated to advancing this field through cutting-edge technology and innovative solutions.
Nebulizers: Paving the Way for Patient-Centric Treatment
For COPD patients, the choice of inhalation device is pivotal. Nebulizers emerge as a game-changer, offering unparalleled ease and comfort during medication intake. Unlike pressurized Metered Dose Inhalers (pMDI) and Dry Powder Inhalers (DPI), nebulizers demand minimal coordination and effort, ensuring a stress-free experience for patients[1]. With continuous aerosol production and the ability to administer medication through tidal-volume breathing, nebulizers enhance treatment adherence, resulting in improved health outcomes.
Strategic Use in Drug Development
In the realm of inhaled medication development, AeproMED advocates for the strategic use of nebulizers, particularly during Phase I clinical trials. Dr. John N Pritchard, CTO of Philips Respironics Drug Delivery, recommends pharmaceutical companies leverage nebulizers to navigate propellant and carrier issues, ultimately streamlining the particle size reduction process. This not only reduces costs and saves time but also accelerates the overall development of inhaled dosage forms[2].
Nebulizer Classification: AeproMED Leading the Way
Nebulizers come in various types, including jet (JN), ultrasonic (UN), and vibrating mesh (VWN). Analyzing clinical trials conducted between 2000 and 2016, 60% of pharmaceutical companies and clinicians preferred VWN, showcasing its dominance over JN (36%) and UN (4%)[3]. In academic research, VWN has emerged as the frontrunner, surpassing JN and UN in published papers. AeproMED, specializing in Vibrating Mesh Nebulizer (VMN) technology, is at the forefront of this shift, offering state-of-the-art solutions in nebulization therapy.
AeproMED Innovation Corp., Ltd.: Your Partner in Intelligent Aerosol Drug Delivery
AeproMED Innovation Corp., Ltd. is a pioneering medical equipment manufacturer specializing in VMN technology. Our dynamic team, comprising experts in diverse fields such as science, engineering, medicine, and entrepreneurship, has developed the revolutionary AirHyper platform. This cutting-edge platform integrates Adaptive Frequency Delivery Technology (AFDT), Digital Synchronized Breath Monitor Technology (DSMT), a tunable material module, and AI intelligent atomization.
Our product range spans anesthesia-free animal nebulizers to human clinical trial nebulizers, ensuring a comprehensive approach to nebulization therapy. Moreover, our state-of-the-art atomization analysis laboratory empowers us to delve into the physical properties of nebulized molecules, predicting their distribution within the lungs.
Collaborate with AeproMED for Precision Medicine
At AeproMED, our mission is to collaborate with pharmaceutical, biotechnology, and ICT technology manufacturers, as well as hospitals, to develop an intelligent atomized drug delivery platform. This platform goes beyond traditional nebulization, integrating physiological data monitoring to ensure optimal drug inhalation. Together, we strive to achieve precision medicine and revolutionize the landscape of inhalation therapy.
Join AeproMED in reshaping the future of respiratory health. Experience the innovation, embrace the intelligence, and breathe life into a new era of inhalation therapy.
References:
1. Dhand, R., et al., The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012. 9(1): p. 58-72.
2. Pritchard, J., Nebulisers: Time to Reinvent the Wheel. ONdrugDelivery Magazine, 2018(92): p. 10-15.
3. Pritchard, J.N., et al., Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments. Therapeutic Delivery, 2018. 9(2): p. 121-136.
